摘要
目的评价曲美他嗪联合比索洛尔治疗冠心病伴心力衰竭的效果及安全性。方法选取2018年4月至2020年4月我院收治的150例冠心病伴心力衰竭患者,根据系统抽样法将其分为对照组(75例,曲美他嗪)和试验组(75例,曲美他嗪联合比索洛尔)。比较两组的临床疗效、不良反应发生情况、心率变异性指标及血管内皮功能指标。结果试验组的治疗总有效率为93.33%,高于对照组的81.33%,差异具有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。治疗前,两组的SDANN、rMSSD、PNN50比较,差异无统计学意义(P>0.05);治疗后,两组的SDANN、rMSSD、PNN50均升高,且试验组高于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的ET-1、CGRP、TXB2水平比较,差异无统计学意义(P>0.05);治疗后,两组的ET-1、CGRP、TXB2水平均改善,且试验组优于对照组,差异具有统计学意义(P<0.05)。结论曲美他嗪联合比索洛尔治疗冠心病伴心力衰竭患者不仅能够有效提高临床治疗效果,而且能显著改善患者的心率变异性和血管内皮功能,安全性较高,值得临床推广应用。
Objective To evaluate the effect and safety of trimetazidine combined with bisoprolol in the treatment of coronary heart disease complicated with heart failure.Methods One hundred and fifty patients with coronary heart disease complicated with heart failure admitted to our hospital from April 2018 to April 2020 were selected and divided into control group(75 cases,trimetazidine) and experimental group(75 cases,trimetazidine combined with bisoprolol)according to the systematic sampling method.The clinical efficacy,adverse reactions,heart rate variability indexes and vascular endothelial function indexes of the two groups were compared.Results The total effective rate of treatment in the experimental group was 93.33%,which was higher than 81.33% in the control group,and the difference was statistically significant(P <0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Before treatment,there were no significant differences in the SDANN,rMSSD and PNN50 between the two groups(P>0.05);after treatment,SDANN,rMSSD and PNN50 in the two groups increased,those in the experimental group were higher than the control group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the ET-1,CGRP and TXB2 levels between the two groups(P >0.05);after treatment,ET-1,CGRP and TXB2 levels in the two groups improved,those in the experimental group were better than the control group,and the differences were statistically significant(P <0.05).Conclusion Trimetazidine combined with bisoprolol in the treatment of patients with coronary heart disease complicated with heart failure can not only effectively improve the clinical treatment effect,but also significantly improve the heart rate variability and vascular endothelial function,with high safety,which is worthy of clinical promotion and application.
作者
李晓妮
韩雪
LI Xiaoni;HAN Xue(the People's Hospital of Huyi District,Xi'an 710300;Traditional Chinese Medicine Hospital of Xixiang County,Hanzhong 723500,China)
出处
《临床医学研究与实践》
2022年第1期50-53,共4页
Clinical Research and Practice
关键词
曲美他嗪
比索洛尔
冠心病
心力衰竭
心率变异性
血管内皮功能
trimetazidine
bisoprolol
coronary heart disease
heart failure
heart rate variability
vascular endothelial function
